07:37 AM EDT, 09/25/2024 (MT Newswires) -- AbbVie ( ABBV ) said Wednesday that the new post-hoc analysis from the company's phase 3 studies of Rinvoq, upadacitinib, in patients with moderate to severe atopic dermatitis in the head and neck region showed "positive" results.

The analysis assessed multiple treatment targets, including near complete skin clearance, minimal itch and minimal impact on quality of life over 16 weeks compared with placebo.

The company also said the analysis showed that a higher proportion of patients with moderate-to-severe atopic dermatitis treated with Rinvoq achieved the optimal treatment targets compared with placebo at week 16.

The key findings from the analysis include near-complete skin clearance in the head and neck region, improvement in quality of life and simultaneous achievement of near-complete skin clearance and no to little itch.

Price: 193.80, Change: +0.29, Percent Change: +0.15